COGT
Cogent Biosciences, Inc.
Stock
$31.02−0.57 (−1.80%)Close Oct 2, 2026
Cash flow statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | −$308M | −$264M | −$208M | −$154M | −$119M | −$59M | −$36M | −$42M | −$32M | −$26M |
| Capital expenditures | $1.7M | $1.6M | $573K | $2.8M | $6.9M | $1.7M | — | $33K | $549K | $912K |
| Free cash flow | −$309M | −$266M | −$208M | −$156M | −$126M | −$60M | — | −$42M | −$33M | −$27M |
| Stock-based compensation | $60M | $46M | $40M | $31M | $18M | $12M | $6.0M | $3.2M | $3.1M | $1.3M |
| Free cash flow margin | — | — | — | — | — | — | — | −184.7% | −339.4% | −319.9% |